Grace expands CDMO capacity by 25% of South Haven facility in Michigan
Additional capacity broadens Grace’s fine chemical capabilities for API production
Additional capacity broadens Grace’s fine chemical capabilities for API production
BHL will undertake the development and supply of these molecules
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Development services for gene and cell therapies is planned to begin first in 2025
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Subscribe To Our Newsletter & Stay Updated